Voya Investment Management LLC Sells 10,205 Shares of Henry Schein, Inc. $HSIC

Voya Investment Management LLC lowered its holdings in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 27.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 26,716 shares of the company’s stock after selling 10,205 shares during the quarter. Voya Investment Management LLC’s holdings in Henry Schein were worth $1,773,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Wellington Management Group LLP grew its holdings in Henry Schein by 15.9% during the 1st quarter. Wellington Management Group LLP now owns 7,996 shares of the company’s stock valued at $548,000 after buying an additional 1,094 shares in the last quarter. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Henry Schein by 1,357.1% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 4,182 shares of the company’s stock worth $286,000 after buying an additional 3,895 shares in the last quarter. Trexquant Investment LP boosted its position in shares of Henry Schein by 27.3% during the first quarter. Trexquant Investment LP now owns 11,213 shares of the company’s stock worth $768,000 after acquiring an additional 2,403 shares during the last quarter. Magnetar Financial LLC purchased a new position in Henry Schein during the first quarter valued at $1,809,000. Finally, Vident Advisory LLC increased its holdings in Henry Schein by 45.8% in the 1st quarter. Vident Advisory LLC now owns 5,120 shares of the company’s stock valued at $351,000 after acquiring an additional 1,608 shares during the last quarter. 96.62% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. Wall Street Zen raised shares of Henry Schein from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Morgan Stanley increased their price target on Henry Schein from $55.00 to $58.00 and gave the company an “underweight” rating in a research note on Wednesday, November 5th. Weiss Ratings restated a “hold (c)” rating on shares of Henry Schein in a report on Monday, December 22nd. Barclays initiated coverage on Henry Schein in a report on Monday, December 8th. They set an “overweight” rating and a $86.00 price objective on the stock. Finally, JPMorgan Chase & Co. raised their target price on shares of Henry Schein from $76.00 to $78.00 and gave the company an “overweight” rating in a report on Wednesday, November 5th. Six investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Henry Schein currently has an average rating of “Hold” and an average target price of $76.92.

Henry Schein Stock Down 0.1%

Shares of HSIC opened at $76.13 on Monday. The company has a quick ratio of 0.79, a current ratio of 1.40 and a debt-to-equity ratio of 0.54. The business has a fifty day moving average of $71.79 and a 200 day moving average of $69.96. The company has a market cap of $8.96 billion, a PE ratio of 24.09, a P/E/G ratio of 2.33 and a beta of 0.89. Henry Schein, Inc. has a 52-week low of $60.56 and a 52-week high of $82.49.

Henry Schein (NASDAQ:HSIC) last released its quarterly earnings results on Tuesday, November 4th. The company reported $1.38 EPS for the quarter, topping analysts’ consensus estimates of $1.27 by $0.11. Henry Schein had a net margin of 3.02% and a return on equity of 14.76%. The firm had revenue of $3.34 billion during the quarter, compared to analysts’ expectations of $3.28 billion. Henry Schein has set its FY 2025 guidance at 4.880-4.960 EPS. On average, sell-side analysts expect that Henry Schein, Inc. will post 4.74 EPS for the current year.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.